Breaking Down Barriers to Detection and Care in Early-Age-Onset Colorectal Cancer in Canada
Curr Oncol. 2023 Oct 24;30(11):9392-9405. doi: 10.3390/curroncol30110680.ABSTRACTThe second Early-Age-Onset Colorectal Cancer Symposium, convened in October 2022, sought solutions to the barriers to early detection and care for colorectal cancer in Canada. This meeting built on a previous symposium, held in 2021 and reported in this journal. Early-age-onset colorectal cancer (EAOCRC) affects increasing numbers of people under the age of 50 in Canada and throughout the developed world. Two main themes emerged from the meeting: the importance of timely detection, and the need for a tailored approach to the care of EAOCRC. Ea...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Michael J Raphael Petra Wildgoose Filomena Servidio-Italiano Mary A De Vera Darren Brenner Monika Slovinec D'Angelo Robin McGee Scott Berry Clarence Wong Sharlene Gill Source Type: research
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
Curr Oncol. 2023 Oct 24;30(11):9406-9427. doi: 10.3390/curroncol30110681.ABSTRACTThe gastrointestinal microbiome has been shown to play a key role in determining the responses to cancer immunotherapy, including immune checkpoint inhibitor (ICI) therapy and CAR-T. In patients with non-small cell lung cancer (NSCLC), increasing evidence suggests that a microbiome composition signature is associated with clinical response to ICIs as well as with the development of immune-related adverse events. In support of this, antibiotic (ATB)-related dysbiosis has been consistently linked with the deleterious impact of ICI response, shor...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Sreya Duttagupta Taiki Hakozaki Bertrand Routy Meriem Messaoudene Source Type: research
Population-Based Survival Analysis of Stage IVB Small-Cell Neuroendocrine Carcinoma in Comparison to Major Histological Subtypes of Cervical Cancer
Curr Oncol. 2023 Oct 24;30(11):9428-9436. doi: 10.3390/curroncol30110682.ABSTRACTThe aim of the current study is to investigate the survival outcome of stage IVB SCNEC of the uterine cervix in comparison to major histological subtypes of cervical cancer. A population-based retrospective cohort study was conducted using the Osaka Cancer Registry data from 1994 to 2018. All FIGO 2009 stage IVB cervical cancer patients who displayed squamous cell carcinoma (SCC), adenocarcinoma (A), adenosquamous cell carcinoma (AS), or small-cell neuroendocrine carcinoma (SCNEC) were first identified. The patients were classified into groups...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Seiji Mabuchi Naoko Komura Tomoyuki Sasano Mina Sakata Shinya Matsuzaki Tsuyoshi Hisa Shoji Kamiura Toshitaka Morishima Isao Miyashiro Source Type: research
Introduction of Androgen Receptor Targeting shRNA Inhibits Tumor Growth in Patient-Derived Prostate Cancer Xenografts
Curr Oncol. 2023 Oct 24;30(11):9437-9447. doi: 10.3390/curroncol30110683.ABSTRACTPatient-derived xenograft (PDX) models have been established as important preclinical cancer models, overcoming some of the limitations associated with the use of cancer cell lines. The utility of prostate cancer PDX models has been limited by an inability to genetically manipulate them in vivo and difficulties sustaining PDX-derived cancer cells in culture. Viable, short-term propagation of PDX models would allow in vitro transfection with traceable reporters or manipulation of gene expression relevant to different studies within the prostate...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Patrick B Thomas Saeid Alinezhad Andre Joshi Katrina Sweeney Brian W C Tse Gregor Tevz Stephen McPherson Colleen C Nelson Elizabeth D Williams Ian Vela Source Type: research
Cancer and Pregnancy in the Post-Roe v. Wade Era: A Comprehensive Review
This article addresses the complicated nature of a diagnosis of cancer in pregnancy, touching upon the known medical literature as well as the ethical-legal implications of such a diagnosis, whose importance has increased in the light of recent judicial developments.PMID:37999104 | PMC:PMC10669942 | DOI:10.3390/curroncol30110684 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Ganguly Arup Narmala Shravan Source Type: research
Pneumonectomy for Primary Lung Tumors and Pulmonary Metastases: A Comprehensive Study of Postoperative Morbidity, Early Mortality, and Preoperative Clinical Prognostic Factors
CONCLUSION: Pneumonectomy for thoracic malignancies remains a high-risk major lung resection with significant postoperative morbidity and mortality. Attention should be paid to the preoperative selection of patients.PMID:37999105 | PMC:PMC10670891 | DOI:10.3390/curroncol30110685 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Konstantinos Grapatsas Hruy Menghesha Fabian D örr Natalie Baldes Martin Schuler Martin Stuschke Kaid Darwiche Christian Taube Servet B ölükbas Source Type: research
Effect of Breast Screening Regimen on Breast Cancer Outcomes: A Modeling Study
Curr Oncol. 2023 Oct 25;30(11):9475-9483. doi: 10.3390/curroncol30110686.ABSTRACTGuidelines vary for the age at which to begin breast cancer screening and the interval between examinations. A validated computer model was used to compare estimated outcomes between various screening regimens. The OncoSim-Breast microsimulation model (Canadian Partnership Against Cancer) was used to simulate a cohort of 1.53 million Canadian women born in 1975. The effect of screening regimen on absolute breast cancer mortality rates, stage at diagnosis, number needed to be screened to avert a breast cancer death or save a life year, abnormal...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Martin J Yaffe James G Mainprize Source Type: research
High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer
In conclusion, this is the first study of the clinical significance of FAF1 in NSCLC, showing that FAF1 overexpression is associated with a poor prognosis in NSCLC and that FAF1 acts as a dangerous factor rather than an apoptosis promoter in NSCLC.PMID:37999107 | PMC:PMC10670600 | DOI:10.3390/curroncol30110687 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: De Hu Hidetaka Yamada Katsuhiro Yoshimura Tsutomu Ohta Kazuo Tsuchiya Yusuke Inoue Kazuhito Funai Takafumi Suda Yuji Iwashita Takuya Watanabe Hiroshi Ogawa Nobuhito Kurono Kazuya Shinmura Haruhiko Sugimura Source Type: research
Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.PMID:37999108 | PMC:PMC10670337 | DOI:10.3390/curroncol30110688 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Rushi Shah Clarissa Polen-De Michaela McGree Angela Fought Amanika Kumar Source Type: research
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
CONCLUSIONS: Immune checkpoint inhibitor (ICI) therapy has become a standard recommendation in curative intent therapy for stage III NSCLC.PMID:37999109 | PMC:PMC10670056 | DOI:10.3390/curroncol30110689 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Arani Sathiyapalan Ziad Baloush Peter M Ellis Source Type: research
Colorectal Cancer in Individuals with Cirrhosis: A Population-Based Study Assessing Practice Patterns, Outcomes, and Predictors of Survival
This study reports poor survival in those with cirrhosis who undergo treatment for CRC. Caution should be taken when considering aggressive treatment.PMID:37999110 | PMC:PMC10670829 | DOI:10.3390/curroncol30110690 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Sunil Patel Kelly Brennan Lisa Zhang Maya Djerboua Sulaiman Nanji Shaila Merchant Jennifer Flemming Source Type: research
Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review
Curr Oncol. 2023 Oct 30;30(11):9542-9568. doi: 10.3390/curroncol30110691.ABSTRACTEsophageal cancer is a highly aggressive and deadly disease, ranking as the sixth leading cause of cancer-related deaths worldwide. Despite advances in treatment, the prognosis remains poor. A multidisciplinary approach is crucial for achieving complete remission, with treatment options varying based on disease stage. Surgical intervention and endoscopic treatment are used for localized cancer, while systemic treatments like chemoradiotherapy and targeted drug therapy play a crucial role. Molecular markers such as HER2 and EGFR can be targeted...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Rakesh Acharya Ananya Mahapatra Henu Kumar Verma L V K S Bhaskar Source Type: research
Psychological Distress and Concerns of In-Home Older People Living with Cancer and Their Impact on Supportive Care Needs: An Observational Survey
Conclusions: Supportive care needs arise from a greater concern and specific type of cancer, highlighting the need for supportive care, such as psychosocial and psychological support. This may have significant implications for treatment and patient outcomes in home care settings.PMID:37999112 | PMC:PMC10670276 | DOI:10.3390/curroncol30110692 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Christos Kleisiaris Maria Maniou Savvato Karavasileiadou Constantinos Togas Theocharis Konstantinidis Ioanna V Papathanasiou Konstantinos Tsaras Wafa Hamad Almegewly Emmanouil Androulakis Hanan Hamdan Alshehri Source Type: research
Advances in the Surgical Treatment of Breast Cancer
Curr Oncol. 2023 Oct 31;30(11):9584-9586. doi: 10.3390/curroncol30110693.ABSTRACTBreast cancer is the most commonly occurring cancer in women and has become the most common cancer diagnosed worldwide [...].PMID:37999113 | PMC:PMC10670006 | DOI:10.3390/curroncol30110693 (Source: Current Oncology)
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Rona Cheifetz Elaine McKevitt Source Type: research
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
Curr Oncol. 2023 Oct 31;30(11):9587-9601. doi: 10.3390/curroncol30110694.ABSTRACTPancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing increasing incidence. The aim of our review is to provide practical help for all clinical oncologists and to summarize the current management of PDAC using a simple "ABC method" (A-anatomical resectability, B-biological resectability and C-clinical conditions). For anatomically resectable PDAC without any high-risk factors (biological or conditional), the actual standard of care is represented by surgery followed by adjuvant chemotherapy. The remaining PDAC pati...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Ingrid Garajov á Marianna Peroni Fabio Gelsomino Francesco Leonardi Source Type: research
